![]() Presenters: Catherine Bollard, Children’s National Hospital, Anthony Coyle, Repertoire Immune Medicines, Stephen Elledge, Harvard University, Claude Perreault, University of Montreal, Ivelin Georgiev, Vanderbilt University, Jenny Jiang, University of Pennsylvania, Alessandro Sette, La Jolla Institute for Immunology, Anish Suri, Cue Biopharma, and Mark Yarmarkovich, University of Pennsylvania. Organizers: Karsten Sauer, PhD, Vice President, Pre-clinical Research and Development, Cullinan Oncology, Michael Birnbaum, PhD, Associate Professor, Massachusetts Institute of Technology, Cambridge, MA Learn how proactive support helps avoid problems before they occur and reduces the time spent on resolving active support requests. Additional speakers will discuss how they are developing powerful immunotherapies based on decoded immune repertoires. Recent advances in single cell sequencing technologies and large-scale HLA tetramer or HLA reporter gene-based epitope library screening technologies have made decoding the "immune synapse" possible. This information promises to enable next generation clonotype or epitope targeted immunotherapies for cancer, autoimmune or infectious diseases that are both more efficacious and safer than current therapies. Our comparative analysis of the BCR repertoire in immune- mediated disease reveals a complex B cell architecture, providing a platform for understanding pathological mechanisms and designing treatment strategies.Leading experts will introduce the audience to recent advances in decoding the specific T cell or B cell clonotypes mediating or protecting from disease along with their recognized antigen epitopes in the context of human HLA haplotypes. Different immunosuppressive treatments had specific and distinct effects on the repertoire B cells that persisted after treatment with rituximab were predominately isotype-switched and clonally expanded, whereas the inverse was true for B cells that persisted after treatment with mycophenolate mofetil. Firstly, we found that the diversity and abundance of the immune repertoire in late DN were significantly increased, while there was no significant change in early DN. vitamin B6 aids in protecting health, preventing disease, and. An increase in clonality in systemic lupus erythematosus and Crohn’s disease that was dominated by the IgA isotype, together with skewed use of the IGHV genes in these and other diseases, suggested a microbial contribution to pathogenesis. Repertoire Based on 1 B3 and 1 B6 Chemical and Biological. Here, we compared the BCR repertoire in systemic lupus erythematosus, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Crohn’s disease, Behçet’s disease, eosinophilic granulomatosis with polyangiitis, and immunoglobulin A (IgA) vasculitis by analysing BCR clonality, use of immunoglobulin heavy-chain variable region (IGHV) genes and-in particular-isotype use. Our understanding of the BCR repertoire in the context of immune-mediated diseases is incomplete, and defining this could provide new insights into pathogenesis and therapy. Our comparative analysis of the BCR repertoire in immune- mediated disease reveals a complex B cell architecture, providing a platform for understanding pathological mechanisms and designing treatment strategies. Different immunosuppressive treatments had specific and distinct effects on the repertoire B cells that persisted after treatment with rituximab were predominately isotype-switched and clonally expanded, whereas the inverse was true for B cells that persisted after treatment with mycophenolate mofetil. An increase in clonality in systemic lupus erythematosus and Crohn’s disease that was dominated by the IgA isotype, together with skewed use of the IGHV genes in these and other diseases, suggested a microbial contribution to pathogenesis. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |